Literature DB >> 12753630

An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic.

Ellie R Carmody1, Theresa Diaz, Paulo Starling, Ana Paula Rocha Beruth dos Santos, Henry S Sacks.   

Abstract

The Brazilian public health system has implemented free, universal access to antiretroviral (ARV) therapy for HIV-infected patients. To evaluate this system, we performed a pilot study to determine whether ARVs were prescribed according to Brazilian guidelines in place in 2000, and whether prescriptions were refilled in a timely manner. Year 2000 data were abstracted from all medical and pharmacy records of adult patients first registered for HIV/AIDS care in a Rio de Janeiro public clinic from January to June 2000 (n = 67). Results were analysed using frequency analyses, chi-square tests and logistic regression. The patient sample was 41.8% female and had a mean age of 34.9 years. 54 (81%) had AIDS; total sample mean baseline CD4+/viral counts were 276 cells/mm3 and 237 517 copies per millilitre, respectively. Delays between clinic request and receipt of first CD4+/viral load results ranged from 25 to 107 (mean 66) and 33 to 139 (mean 86) days, respectively. Fifty-nine patients (88.1%) were prescribed ARV treatment. Forty-two regimens (71.2%) were highly active antiretroviral therapies; 17 (28.8%) were combination regimens with two nucleoside reverse transcriptase inhibitors. No combinations were prescribed that were contraindicated in Brazilian guidelines, however 33 patients (55.9%) were prescribed ARV drugs before one or both HIV status parameters (initial CD4+ level or viral load) were recorded. Fourteen patients prescribed ARVs (23.7%) lacked a supply of medication for >1 month during the year at least once. Of these patients, 11 had treatment lapses as a result of failure to pick up medications, and three lacked medication because of drug shortages. Medication lapses were associated with female sex, being hospitalized in 2000, and having more than two drugs in regimen, but were not associated with age, CD4+ level or use of ARVs before 2000. The results from this pilot study suggest conservative prescription of HAART, high practitioner adherence to guidelines, and some problems with refilling medications in a timely manner. Monitoring delays were identified as a structural limitation to optimal adherence to practice guidelines. Better access to monitoring-laboratory facilities and greater drug availability would improve programme success.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753630     DOI: 10.1046/j.1365-3156.2003.01046.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  4 in total

Review 1.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

2.  Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis.

Authors:  Nienke Langebeek; Elizabeth H Gisolf; Peter Reiss; Sigrid C Vervoort; Thóra B Hafsteinsdóttir; Clemens Richter; Mirjam A G Sprangers; Pythia T Nieuwkerk
Journal:  BMC Med       Date:  2014-08-21       Impact factor: 8.775

3.  Epidemiology of Opportunistic Infections in HIV Infected Patients on Treatment in Accredited HIV Treatment Centers in Cameroon.

Authors:  Ornella Sybile D Kouanfack; Charles Kouanfack; Serges Clotaire Billong; Samuel N Cumber; Claude N Nkfusai; Fala Bede; Emerson Wepngong; Chombong Hubert; Georges Nguefack-Tsague; Madeleine N Singwe
Journal:  Int J MCH AIDS       Date:  2019-12-18

4.  Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.

Authors:  Abraham Miranda; Meade Morgan; Leda Jamal; Kayla Laserson; Draurio Barreira; Guida Silva; Joseney Santos; Charles Wells; Patricia Paine; Denise Garrett
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.